drug
GI-102
Phase 2updated 7mo agoby GI Innovation Co Ltd
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying GI-102
- phase2A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
- phase2A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
News(2)
- RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early dataThe new data could help boost Revolution Medicines beyond the currently estimated $14.5 billion in peak sales for the recently approved RAS(ON) inhibitor, Truist Securities predicts.biospace · 1d ago
- ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported…biospace · 29d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that